N,N-Dibenzyloxycarbonylhydrazine | 97411-44-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-Dibenzyloxycarbonylhydrazine
• 英文别名: bis(benzyloxycarbonyl)hydrazine；N,N-dibenzylcarbazate；NH2NCbz2；benzyl N-amino-N-phenylmethoxycarbonylcarbamate
• CAS: 97411-44-4
• 化学式: C₁₆H₁₆N₂O₄
• 分子量: 300.314
• InChiKey: STKCQTPTVUWWCW-UHFFFAOYSA-N

物化性质

• 熔点：
  106.5 °C
• 沸点：
  449.8±48.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  81.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N,N-Dibenzyloxycarbonylhydrazine 在 盐酸 、 sodium nitrite 作用下， 生成 替卡格雷中间体
  参考文献：
  名称：

  Milcent, Rene; Guevrekian-Soghomoniantz, Marina; Barbier, Geo, Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 1845 - 1848

  摘要：

  DOI：
• 作为产物：
  描述：

  Benzaldehyde dibenzyloxycarbonylhydrazone 在 碳酰肼 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 1.5h， 以60%的产率得到N,N-Dibenzyloxycarbonylhydrazine
  参考文献：
  名称：

  Milcent, Rene; Guevrekian-Soghomoniantz, Marina; Barbier, Geo, Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 1845 - 1848

  摘要：

  DOI：

文献信息

• [EN] IMPROVED PROCESS FOR THE MANUFACTURE OF 1,2-DISUBSTITUTED HEXAHYDROPYRIDAZINE-3-CARBOXYLIC ACIDS AND ESTERS THEREOF<br/>[FR] PROCEDE AMELIORE DE FABRICATION D'ACIDES HEXAHYDROPYRIDAZINE-3-CARBOXYLIQUES 1,2-DISUBSTITUES ET LEURS ESTERS
  申请人：HONEYWELL SPECIALTY CHEMICALS

  公开号：WO2005028449A1

  公开（公告）日：2005-03-31

  The invention relates to an improved process for the manufacture of 1,2-disubstituted hexahydro-pyridazine-3-carboxylic acids and esters thereof by reacting N,N’-disubstituted hydrazine with 2,5-dihalogenated valeric acids and thereof by means of phase transfer catalysis. Said pyridazine carboxylic acids and esters thereof can be used as intermediates for the production of pharmaceutical products

  该发明涉及一种改进的工艺，通过相转移催化作用，将N,N'-二取代肼与2,5-二卤代戊二酸反应，制备1,2-二取代六氢吡啶并-3-羧酸及其酯。所述吡啶羧酸及其酯可用作制药产品的中间体。
• PEPTIDE DEFORMYLASE INHIBITORS
  申请人：Aubart Kelly M.

  公开号：US20130345120A1

  公开（公告）日：2013-12-26

  The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.

  本发明涉及一种化合物，其化学式为（I）：或其药学上可接受的盐，相应的制药组合物，化合物制备和治疗方法，用于治疗细菌感染和抑制细菌肽变形酶（PDF）活性。
• Peptide deformylase inhibitors
  申请人：Aubart Kelly M.

  公开号：US08901119B2

  公开（公告）日：2014-12-02

  The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.

  本发明涉及一种化合物，其化学式为（I）：或其药用可接受的盐，相应的药物组合物，化合物制备和治疗方法，用于治疗细菌感染和抑制细菌肽变形酶（PDF）活性。
• XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS
  申请人：Hatley Richard Jonathan Daniel

  公开号：US20100179128A1

  公开（公告）日：2010-07-15

  The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for the manufacture of said derivatives, pharmaceutical formulations containing these active compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial

  本发明涉及式(I)的化合物，它们是黄嘌呤衍生物，制造这些衍生物的方法，含有这些活性化合物的制药配方，以及在治疗中使用这些化合物，例如，用于治疗HM74A受体欠活化导致疾病或激活该受体将有益的疾病。
• Synthesis of fluorinated N-aminoaziridines: access to new CF3-peptidomimetics
  作者：Bertrand Schweitzer-Chaput、Massaba Keita、Thierry Milcent、Sandrine Ongeri、Benoit Crousse

  DOI：10.1016/j.tet.2012.06.093

  日期：2012.9

  A series of fluorinated N-aminoaziridines have been synthesized by the PhI(OAc)(2)-mediated aziridination procedure. The reaction was carried out with various protected hydrazides and fluorinated alkenes. The reaction was extended to alkenes bearing an amino acid and the ring opening of the CF3-N-aminoaziridines has been investigated. (C) 2012 Elsevier Ltd. All rights reserved.